Prognostic signatures are also known as Gene Expression Profiles (GEP) are now commonly used in the clinic to stratify hormone positive breast cancer patients risk of distant recurrence at 10 years and aid treatment strategy decision making. In this blog post, I will review the commonly used GEP and hopefully illustrate their proper clinical utilization as well as limitations. In a previous post, I discussed the adjuvant endocrine therapy for hormone positive breast cancer, for details please click here.
The use of GEP in Early stage breast cancer signficantly reduced the use of Chemotherapy in this patient population.
Continue reading “Prognostic Signatures in Breast Cancer”
In this blog post, I will review the current recommendation of endocrine therapy for early non-metastatic breast cancer hormone positive breast cancer (Estrogen receptor positive ER + and/or Progesterone receptor positive PR +), this is most often referred to as Adjuvant hormonal or Adjuvant Endocrine therapy, for discussion regarding the use of endocrine therapy for metastatic breast cancer please refer to my earlier post by clicking here.
Hormone receptor-positive Breast cancer comprise 75% of all cases.
Endocrine therapy is of significant benefit and Generally well tolerated.
Continue reading “Endocrine Therapy for Early Breast Cancer”